股票
板块
用户
资讯
首页
天眼
自选
发现
开户
首页
天眼
自选
发现
我的

国内首款mRNA in vivo CAR-T产品!美迪西助力合作伙伴瑞宏迪医药RGL-208获批临床|Bilingual

11月3日,上海瑞宏迪医药有限公司自主研发的双靶点体内CAR-T产品RGL-208注射液正式获得国家药品监督管理局(NMPA)临床试验默示许可,拟用于复发/难治性 B 细胞非霍奇金淋巴瘤的治疗。RGL-208是国内首款获批临床的mRNA in vivo CAR-T产品,也是公司首款进入临床开发阶段的体内CAR-T产品。

美迪西助力

美迪西作为瑞宏迪医药的合作伙伴,为RGL-208提供了支持NMPA、FDA及OECD I 期临床试验申报的药代动力学和安全评价研究服务,助力该药物顺利进入临床阶段。

临床痛点?未竟之需 

现有CAR-T疗法制备复杂、周期长

可及性亟待突破

复发/难治性B细胞恶性血液肿瘤异质性强、易复发,患者多线治疗后预后不佳,临床需求迫切。虽多款CAR-T产品已获批上市带来治愈希望,但现有疗法均采用体外个体化制备,流程复杂、周期长、成本高,且单靶点设计面临靶抗原丢失、CAR-T 细胞耗竭等等复发挑战,严重限制了疗法可及性,如何提高可及性,让更多患者快速用上CAR-T疗法已成为细胞治疗领域的核心挑战之一。

双靶点设计?现货型CAR-T 

体内原位生成CAR-T细胞

让细胞治疗迈向「现货型」

RGL-208注射液是瑞宏迪医药自主研发的一款双靶点体内CAR-T(in vivo CAR-T)产品,作为国内首款获批临床的mRNA体内CAR-T产品,为破解传统CAR-T疗法痛点、提升细胞治疗可及性开辟全新路径。

采用mRNA-LNP递送技术:将mRNA编码的CAR基因片段特异性递送至患者体内的T细胞,在体内高效生成CAR-T细胞,从而实现对肿瘤细胞的识别与杀伤

双靶点设计,降低复发风险:同时靶向两个抗原,有助于减少因单一靶点丢失或下调导致的肿瘤细胞逃逸,降低复发风险。

「现货型」产品,无需个体化制备:患者无需接受细胞单采和等待体外制备,经静脉给药即可完成治疗,将治疗等待周期大幅缩短。

显著降低生产与治疗可及性门槛:mRNA-LNP路线具备标准化、规模化生产潜力,有望降低生产成本,让前沿细胞疗法惠及更广泛的患者群体。

RGL-208的IND获批,标志着瑞宏迪医药在in vivo CAR-T领域实现关键性突破,跻身国内体内CAR-T临床转化第一梯队,持续印证自研技术平台的创新活力与转化落地能力。

平台赋能?技术助力 

美迪西CGT服务平台

助力细胞与基因治疗药物临床前研发

在RGL-208临床前研发中,美迪西依托流式细胞术、ELISA、PCR、LC-MS/MS等多平台分析技术,系统性完成体内药效与毒性评价。针对 RGL-208 注射液食蟹猴毒理研究,结合产品特点建立免疫相关反应的监测与急救预案;在人源化免疫缺陷小鼠药理试验中,精准构建动物模型,在数据解读中充分排除模型背景病变干扰,从而对RGL-208的药效和安全性作出科学、完整的解读与评价。

深耕CGT领域,美迪西已建立了完善的CGT研发服务平台,涵盖CAR-T(含in vivo CAR-T)、TCR-T、CAR-NK、TIL等主流免疫细胞治疗技术, 可提供药理药效、药代动力学、生物分析、药物安全性评价等服务,已助力9个细胞治疗药物获批临床。

MEDICILON

美迪西祝贺瑞宏迪医药RGL-208注射液获批进入临床,期待该产品在临床阶段进展顺利,早日让更多患者以更简单、更快速、更可负担的方式用上前沿细胞疗法。未来,美迪西将依托成熟的一站式临床前研发平台与丰富的全球注册申报经验,持续赋能更多创新药物加速从Target到IND。

关于瑞宏迪医药

瑞宏迪医药成立于2021年8月,是一家专注于细胞与基因治疗(CGT)领域的创新型生物制药公司。公司拥有AI助力的“AAV+mRNA+细胞疗法+in vivo CAR-T”四大自主研发技术平台,平台搭载业界领先的质粒、病毒、mRNA及细胞疗法全链条工艺开发和生产质控模块,均实现高产能、高回收率、高质量、低成本,为药物开发提供强大支撑。公司研发管线精准布局于神经、眼科、代谢、肿瘤等临床需求迫切、市场前景广阔的疾病领域。瑞宏迪医药始终以守护人类健康为使命,持续增强核心竞争力,保持开拓创新精神,致力于为全球患者创造更美好的健康生活。

关于美迪西

美迪西(股票代码:688202.SH)成立于 2004 年,专注于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研发服务。公司构建了覆盖药物发现、药学研究至临床前研究的一站式综合研发平台,并在 ADC/AOC、小核酸、多 (环)肽、TPD, RIPTAC等前沿领域搭建了服务平台。公司建立了符合国际规范的质量体系,已获得中国 NMPA、美国 FDA、OECD 等 GLP 认证以及 AAALAC 国际认证。目前,公司在上海和Boston拥有约 9.2 万平方米研发实验室。至 2026 年 6 月末,公司已为全球超 2000 家客户提供药物研发服务,参与研发完成的新药项目已有近700件 IND临床批件。美迪西将继续携手国内外合作伙伴共同推动药物创新,为人类健康贡献力量。欢迎访问公司官网 www.medicilon.com.cn 了解更多详情。

China’s First mRNA-Based In Vivo CAR-T Candidate! Medicilon Supports Regenelead RGL-208 IND Approval

November 3 — RGL-208 Injection, a dual-target in vivo CAR-T candidate independently developed by Regenelead, has received implied clinical trial approval from the NMPA. It is intended for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. RGL-208 marks China’s first mRNA in vivo CAR-T product to enter clinical development, as well as Regenelead’s first in vivo CAR-T candidate advancing into the clinic.

As a partner of Regenelead, Medicilon provided pharmacokinetic and safety assessment studies for RGL-208, satisfying regulatory requirements for the NMPA, FDA and OECD, and enabling the candidate’s smooth transition into clinical testing.

Unmet Clinical Needs: Limitations of Current CAR-T Therapies 

Conventional CAR-T therapies involve complex manufacturing and lengthy lead times, creating major barriers to patient access.

Conventional CAR-T therapies involve complex manufacturing and lengthy lead times, creating major barriers to patient access.

Relapsed/refractory B-cell hematological malignancies are highly heterogeneous and prone to recurrence, with poor outcomes for patients after multiple lines of treatment, representing a substantial unmet medical need. While several approved CAR-T products have offered curative potential, these existing therapies rely on ex vivo personalized manufacturing. The cumbersome workflows, long production cycles and high costs, paired with relapse risks driven by antigen loss and CAR-T cell exhaustion in single-target designs, severely limit accessibility. Expanding access so that more patients can rapidly receive CAR-T treatment remains one of the core challenges in cell therapy.

Dual-Target, Off-the-Shelf In Vivo CAR-T 

Generating In Vivo CAR-T cells to advance cell therapy toward off-the-shelf solutions

RGL-208 Injection is a dual-target in vivo CAR-T candidate discovered and developed by Regenelead. As China’s first mRNA in vivo CAR-T product cleared for clinical investigation, it opens a new route to address key pain points of traditional CAR-T therapies and improve access to cell therapy.

mRNA-LNP delivery platform: mRNA encoding the CAR construct is specifically delivered to patients’ T cells to generate functional in vivo CAR-T cells, which recognize and eliminate tumor cells.

Dual-target design to mitigate relapse: By targeting two antigens simultaneously, RGL-208 helps reduce tumor escape caused by the loss or downregulation of a single antigen..

Off-the-shelf format without individualized manufacturing: Patients can be treated by a single intravenous administration — no leukapheresis, no waiting for in vitro manufacturing, drastically cutting waiting time.

Lower barriers for manufacturing and access: The mRNA-LNP platform offers the potential for standardized, large-scale manufacturing, which could reduce production costs and extend cutting-edge cell therapy to a broader patient population.

The IND approval of RGL-208 represents a landmark breakthrough for Regenelead in in vivo CAR-T research, placing the company among China’s front-runners for clinical translation of in vivo CAR-T programs. It further demonstrates the innovative strength and translational capacity of Regenelead’s proprietary technology platforms.

Platform-Driven Preclinical Support 

Medicilon’s CGT platform powers preclinical development for cell and gene therapies

During RGL-208’s preclinical development, Medicilon deployed a suite of analytical platforms including flow cytometry, ELISA, PCR and LC-MS/MS to conduct systematic in vivo efficacy and toxicity evaluations. For the cynomolgus monkey toxicology program tailored to RGL-208, our team established immune-related response monitoring and emergency-response plans tailored to the product's characteristics. In pharmacology studies using humanized immunodeficient mouse models, Medicilon precisely constructed the animal models and carefully controlled for model-related background lesions during data interpretation, delivering a scientifically rigorous and complete assessment of RGL-208's efficacy and safety.

With deep expertise in cell and gene therapy, Medicilon has built a comprehensive CGT service platform covering leading immune cell modalities including CAR-T (in vivo CAR-T included), TCR-T, CAR-NK and TIL. Our service portfolio spans pharmacology and efficacy studies, pharmacokinetics, bioanalysis and safety evaluation. To date, we have supported nine cell therapy candidates in securing IND approvals.

MEDICILON

With deep expertise in cell and gene therapy, Medicilon has built a comprehensive CGT service platform covering leading immune cell modalities including CAR-T (in vivo CAR-T included), TCR-T, CAR-NK and TIL. Our service portfolio spans pharmacology and efficacy studies, pharmacokinetics, bioanalysis and safety evaluation. To date, we have supported nine cell therapy candidates in securing IND approvals.

Medicilon congratulates Regenelead on the IND clearance of RGL-208 Injection. We look forward to its steady clinical progression and hope this novel therapy will soon bring an easier, faster and more affordable cell treatment to patients. Moving forward, leveraging our mature one-stop preclinical platform and extensive global regulatory filing experience, Medicilon will continue empowering innovative drug developers to accelerate the journey from target discovery to IND.

About Medicilon

Founded in 2004, Medicilon (Stock Code: 688202.SH) is dedicated to delivering comprehensive preclinical drug R&D services to pharmaceutical enterprises, research institutions, and scientific investigators worldwide. The company has established a one-stop integrated R&D platform encompassing drug discovery, pharmaceutical research, and preclinical research, and has developed service platforms in cutting-edge fields including ADC/AOC, RNAi, peptides (including macrocyclic peptides), TPD, and RIPTAC. The company has instituted a quality system compliant with international standards and has secured GLP certifications from China's NMPA, the U.S. FDA, and the EU's OECD, along with AAALAC International accreditation. At present, the company operates approximately 92,000 square meters of R&D laboratory space across Shanghai and Boston. As of the end of June 2026, the company has provided drug R&D services to over 2,000 clients globally and has supported nearly 700 IND approvals. For more information, visit www.medicilon.com.

原文链接
多空观点 观点仅供交流,不构成投资建议
点赞
踩一踩
收藏
分享

评论 (0)

0/200
声明:社区内容仅代表用户个人观点,不构成任何投资建议。投资有风险,入市需谨慎。